Literature DB >> 268381

Paul-Bunnell antigen in lymphoma and leukemia spleens.

K Kano, A Fjelde, F Milgrom.   

Abstract

Lymphoid cells obtained from spleens of patients with lymphomas or leukemias were studied for the presence of heterophile (Paul-Bunnell (P-B)) antigen. A mixed agglutination (MA) test was established utilizing monolayers of cells attached to poly-L-lysine-coated wells of plastic U plates. After incubation of the monolayers with infectious mononeucleosis (IM) sera, indicator cells, sheep, or trypsinized bovine erythrocytes were added. The results were assessed according to sedimentation patterns of the indicator cells on the monolayers. Positive MA reactions were shown to be due to specific binding of P-B antibodies to the corresponding antigens on the spleen cells. Positive results were obtained with 15 of 37 spleens from patients with Hodgkin's disease, 5 of 8 lymphoma spleens, 4 of 15 chronic myelocytic leukemia spleens and 2 of 4 chronic lymphocytic leukemia spleens. Only 2 of 25 spleens from patients with various other diseases and 1 of 26 apparently normal thymus specimens gave positive results. This study confirmed demonstration of P-B antigen in lymphoma and leukemia by means of absorption experiments, which was reported previously.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 268381

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

Review 1.  Herpesviruses.

Authors:  M C Timbury; E Edmond
Journal:  J Clin Pathol       Date:  1979-09       Impact factor: 3.411

Review 2.  Loci and motifs of the GalNAcα1 → 3/O related glycotopes in the mammalian glycoconjugates and their lectin recognition roles.

Authors:  Albert M Wu
Journal:  Glycoconj J       Date:  2022-08-13       Impact factor: 3.009

3.  Autoimmunity induced by syngeneic splenocyte membranes carrying irreversibly adsorbed paramyxovirus.

Authors:  M D Eaton
Journal:  Infect Immun       Date:  1980-03       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.